Accessibility Menu
Molecular Templates logo

Molecular Templates(OTC) MTEM

This security has been delisted. This page is retained for historical reference.

Molecular Templates last closing stock price
MetricPriceDate
Last closeUSD 0.002025-07-21
Molecular Templates stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002025-07-10
1 month+0%USD 0.002025-06-20
3 month+0%USD 0.002025-04-21
Year to date-99.75%USD 0.042024-12-31
1 year-99.99%USD 1.342024-07-19
3 year-100%USD 14.252022-07-22
5 year-100%USD 191.252020-07-22
Since inception-100%USD 90.002017-08-03

MTEM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

MTEM Financials

Key Financial Metrics (TTM)

Gross Margin

87.94%

Operating Margin

-18.26%

Net Income Margin

-14.18%

Return on Equity

148.79%

Return on Capital

-63.65%

Return on Assets

-22.96%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$16.14M

Operating Income

-$8.58M

EBITDA

-$10.51M

Operating Cash Flow

-$23.92M

Capital Expenditure

$0.00

Free Cash Flow

-$23.92M

Cash & ST Invst.

$9.66M

Total Debt

$11.03M

Molecular Templates Performance Analysis

Molecular Templates annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 38,697,000N/A
20222022-12-31USD 19,754,000-49.0%
20232023-12-31USD 57,306,000190.1%
Molecular Templates sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30-1.0%
Q42023-12-313.2%
Q12024-03-3158.0%
Q22024-06-30-94.8%
Molecular Templates annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -22.52N/A
20222022-12-31USD -24.699.6%
20232023-12-31USD -1.80-92.7%
Molecular Templates sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-3071.6%
Q42023-12-3111.0%
Q12024-03-31111.2%
Q22024-06-30-1609.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$572.00K

-91.7%

Gross Profit

-$4.83M

+26.2%

Gross Margin

-8.44%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

62

N/A

Net Income

-$8.10M

+25.5%

EBITDA

-$6.98M

+8.9%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$9.66M

+95.0%

Total Debt

$11.03M

-17.6%

Accounts Receivable

$795.00K

+190.1%

Inventory

$0.00

-100.0%

Long Term Debt

$8.39M

-23.9%

Short Term Debt

$0.00

-100.0%

Return on Assets

-22.96%

N/A

Return on Invested Capital

-57.94%

N/A

Free Cash Flow

-$5.86M

+39.3%

Operating Cash Flow

-$5.86M

+39.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDKMMDEChem, Inc.
$0.00-100.00%
BLEVFBeleave Inc.
$0.00+0.00%
ARTHArch Therapeutics, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
AALAmerican Airlines Group
$13.56-0.08%
INTCIntel
$100.23-0.02%
TSLATesla
$319.69-0.15%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.